Commentary Open Access
Volume 6 | Issue 4 | DOI: https://doi.org/10.33696/cancerimmunol.6.095
A Blood-based Metabolite Signature for Personalized Risk Assessment of Pancreatic Cancer
Ricardo A León-Letelier1, Yihui Chen1, Riccardo Ballaro1, Ehsan Irajizad2, Kim-An Do2, Anirban Maitra3, Jianjun Zhang5, C Max Schmidt4, Johannes F. Fahrmann1,*
- 1Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
- 2Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
- 3Department of Translational Molecular Pathology and Sheikh Ahmed Center for Pancreatic Cancer Research, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
- 4Department of Surgery, Indiana University School of Medicine, Indianapolis, Indiana, USA
- 5Department of Epidemiology, Richard M. Fairbanks School of Public Health, Indiana University, Indianapolis, Indiana, USA
Corresponding Author
Johannes F. Fahrmann, JFFahrmann@mdanderson.org
Received Date: August 12, 2024
Accepted Date: October 03, 2024
León-Letelier RA, Yihui C, Ballaro R, Irajizad E, Do KA, Maitra A, et al. A Blood-based Metabolite Signature for Personalized Risk Assessment of Pancreatic Cancer. J Cancer Immunol. 2024;6(4):148-153.
Copyright: © 2024 León-Letelier RA, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Recommended Articles
Neoadjuvant Therapy (NAT) in Localized Pancreatic Cancer: Should We Do It and What Should We Do?
In 2019, approximately 56,770 new cases of pancreatic cancer were diagnosed in the United States, resulting in an estimated 45,750 deaths. Pancreatic cancer is one of the leading causes of cancer-related death, with a fiveyear survival rate of 9%. Based on the eighth edition of the American Joint Committee on Cancer (AJCC) staging system for pancreatic adenocarcinoma, multi-center analyses have validated that poorer prognosis is associated with node-positive disease (N1 and N2).
A Blood-based Metabolite Signature for Personalized Risk Assessment of Pancreatic Cancer
Pancreatic ductal adenocarcinoma (PDAC) is the third most common cause of cancer-related deaths in the United States. Modeling studies project PDAC to be the second leading cause of cancer-related mortality by 2040. Poor survival rates are attributed to the overwhelming majority (>80%) of patients presenting with locally advanced or metastatic disease, which precludes surgical resection and possibility of a long-term cure.
Combating PDAC Drug Resistance: The Role of Ref-1 Inhibitors in Accelerating Progress in Pancreatic Cancer Research
Pancreatic Ductal Adenocarcinoma (PDAC) remains one of the most lethal solid tumor diagnoses given its limited treatment options and dismal prognosis. Its complex tumor microenvironment (TME), heterogeneity, and high propensity for drug resistance are major obstacles in developing effective therapies. Here, we highlight the critical role of Redox effector 1 (Ref-1) in PDAC progression and drug resistance, focusing on its redox regulation of key transcription factors (TFs) such as STAT3, HIF1α, and NF-κB, which are pivotal for tumor survival, proliferation, and immune evasion.